unpopular opinion: most of what gets said here about TRIUMPH is guesswork
unpopular opinion: most of what gets said here about TRIUMPH is guesswork. Change my mind, genuinely — I have no stake in being right about this.
The standing caveat, written out properly because it keeps getting compressed into a footnote.
Nothing containing this compound is approved by any regulator. Research-use-only material is not approved for human use. That is not a legal formality on this board — it is why there is so little independent data, why the escalation schedules people post are invented, and why nobody here can answer a dosing question.
What this board can usefully do is read the published trials carefully, log independent purity results, and be honest about how thin the evidence base is. Everything else belongs somewhere with a clinician in it.
Stopped at a low step because there was no reason to go further and no data to tell me what further would do.
Where the evidence actually stands, since every thread here assumes a different answer.
Phase 2 reported a large mean body weight change at 48 weeks across a few hundred participants with a slow, protocol-driven escalation. The effect size was striking. The confidence intervals were wide, the population was small, and the duration was under a year.
Phase 3 is running. Until it reports, everything else — including the ranking arguments this board loves — is extrapolation from a small study. That is not a criticism of the compound; it is a description of the evidence.
I will update this if the picture changes rather than quietly leaving it up.
best — the order this archive was captured in
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
Standing reminder in every thread here: unapproved compound, research material is not for human use, nothing on this board is medical advice.
Read the phase 2 paper twice before ordering anything. Recommend that to anyone in this board: the error bars are the interesting part.
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
small trial, big effect, wide error bars
not approved anywhere, which is the single most important fact in this board
not approved anywhere, which is the single most important fact in this board
marta_vanhecke is right about the escalation being the variable. It explains most of the difficult reports here.
Sent a vial to VendorInvestigate out of curiosity. Result was 97.4% against a claimed 97.0%, which is the first independent number I had seen for this compound anywhere.
the phase 2 numbers were striking and they were also 48 weeks in a small population
a lot of the confident posting here is extrapolation
Cosigning the escalation point. Almost every difficult report on this board is from somebody who went up quickly.
heart rate is the thing people report watching
Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.
- 1Read the phase 2 paper twice before ordering anything. Recommend that to…8 comments in this branch · started by u/freya_baptista